title: Long-term temozolomide might be an optimal choice for patient with multifocal glioblastoma, especially with deep-seated structure involvement: a case report and literature review.
abstract: BACKGROUND
  Multifocal glioblastoma is an uncommon and refractory subtype of high-grade glioma since the burden of masses could not be eliminated simply by operation, and it is getting even harder to control if some deep structures, like thalamus and pineal region, are involved.
  
  
  METHODS
  Here we report a case of a 30-year-old male with multifocal glioblastoma affected his right thalamus, left lateral ventricle, and pineal region. Clinical manifestations include operation, concurrent radiochemotherapy, and a 12-cycle adjuvant temozolomide administration. The masses of this patient nearly disappeared after 15 months from the primary diagnosis, and no severe adverse event or neurological sequel occurred.
  
  
  CONCLUSIONS
  Long-term temozolomide might be an optimal choice for patients with multifocal glioblastoma, especially with deep-seated structure involvement.
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. liuyunp6644@126.com.|China National Clinical Research Center for Neurological Diseases, No. 6 Tiantan Xili, Dongcheng District, Beijing, China. liuyunp6644@126.com.
authors.forename: Yunpeng
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. shuyuhao@aliyun.com.|China National Clinical Research Center for Neurological Diseases, No. 6 Tiantan Xili, Dongcheng District, Beijing, China. shuyuhao@aliyun.com.
authors.forename: Shuyu
authors.initials: S
authors.lastname: Hao
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. yulanbing@sohu.com.|China National Clinical Research Center for Neurological Diseases, No. 6 Tiantan Xili, Dongcheng District, Beijing, China. yulanbing@sohu.com.
authors.forename: Lanbing
authors.initials: L
authors.lastname: Yu
authors.affiliation: Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 6 Tiantan Xili, Dongcheng District, Beijing, 100050, China. gaozx@ccmu.edu.cn.|China National Clinical Research Center for Neurological Diseases, No. 6 Tiantan Xili, Dongcheng District, Beijing, China. gaozx@ccmu.edu.cn.
authors.forename: Zhixian
authors.initials: Z
authors.lastname: Gao
mesh_terms: D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D001932:Brain Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D059248:Chemoradiotherapy; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005909:Glioblastoma / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D000077204:Temozolomide
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide